Welcome to our dedicated page for Nrx Pharmaceuticals SEC filings (Ticker: NRXPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nrx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nrx Pharmaceuticals's regulatory disclosures and financial reporting.
NRx Pharmaceuticals outlines a clearer regulatory path for its NRX-100 (preservative-free ketamine) program following an in-person Type C meeting with senior FDA leadership. Based on oral guidance, the company believes it can file a full New Drug Application using existing controlled trial data plus Real World Evidence from more than 65,000 patients in the Osmind database.
The company now plans to seek an indication for treatment-resistant depression in the context of suicidality, a broader target than suicidal ideation alone, and expects no additional nonclinical or bridging studies will be required. FDA will work with NRx and Osmind to finalize a statistical analysis plan for the Real World Evidence, which the company expects will be among the first such CNS applications under new guidance. Separately, NRx has filed an Abbreviated New Drug Application for a generic preservative-free ketamine for anesthesia and pain, with a planned FDA decision date in summer 2026.
NRx Pharmaceuticals outlines a clearer regulatory path for its NRX-100 (preservative-free ketamine) program following an in-person Type C meeting with senior FDA leadership. Based on oral guidance, the company believes it can file a full New Drug Application using existing controlled trial data plus Real World Evidence from more than 65,000 patients in the Osmind database.
The company now plans to seek an indication for treatment-resistant depression in the context of suicidality, a broader target than suicidal ideation alone, and expects no additional nonclinical or bridging studies will be required. FDA will work with NRx and Osmind to finalize a statistical analysis plan for the Real World Evidence, which the company expects will be among the first such CNS applications under new guidance. Separately, NRx has filed an Abbreviated New Drug Application for a generic preservative-free ketamine for anesthesia and pain, with a planned FDA decision date in summer 2026.
NRx Pharmaceuticals, Inc. filed a prospectus supplement covering an at-the-market offering of up to $20,000,000 of its common stock. The shares may be issued from time to time under an existing At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC.
The shares will be issued under the company’s effective Form S-3 shelf registration statement and related base prospectus. This report also files a legal opinion from Cozen O’Connor confirming the validity of the shares to be issued under the program.
NRx Pharmaceuticals, Inc. filed a prospectus supplement covering an at-the-market offering of up to $20,000,000 of its common stock. The shares may be issued from time to time under an existing At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC.
The shares will be issued under the company’s effective Form S-3 shelf registration statement and related base prospectus. This report also files a legal opinion from Cozen O’Connor confirming the validity of the shares to be issued under the program.
NRx Pharmaceuticals is launching an at-the-market stock program to sell up to $20,000,000 of common stock through H.C. Wainwright & Co. as sales agent. Shares may be sold on Nasdaq under the symbol NRXP or in negotiated transactions at prevailing market prices, with HCW earning up to 3.0% of gross proceeds.
The company plans to use any net proceeds for working capital and general corporate purposes to support growth. As of September 30, 2025, net tangible book value was about $(1.02) per share, and an illustrative sale of 11,111,111 shares at $1.80 would leave pro forma net tangible book value at $(0.21) per share, creating immediate dilution of $2.01 per new share. The filing highlights significant risks, including potential dilution, stock price volatility, and possible Nasdaq delisting if listing requirements are not met.
NRx Pharmaceuticals is launching an at-the-market stock program to sell up to $20,000,000 of common stock through H.C. Wainwright & Co. as sales agent. Shares may be sold on Nasdaq under the symbol NRXP or in negotiated transactions at prevailing market prices, with HCW earning up to 3.0% of gross proceeds.
The company plans to use any net proceeds for working capital and general corporate purposes to support growth. As of September 30, 2025, net tangible book value was about $(1.02) per share, and an illustrative sale of 11,111,111 shares at $1.80 would leave pro forma net tangible book value at $(0.21) per share, creating immediate dilution of $2.01 per new share. The filing highlights significant risks, including potential dilution, stock price volatility, and possible Nasdaq delisting if listing requirements are not met.
NRx Pharmaceuticals, Inc. appointed Joseph M. Casper, age 75, as its Chief Operating Officer, effective January 27, 2026. He brings 35 years of healthcare experience, including senior roles advising major payer, provider, and academic medical center organizations and involvement in an early medical record aggregation platform used by more than 15 million patients.
Mr. Casper’s compensation includes an expected annual base salary of $250,000, a target bonus of 25% of base salary tied to agreed milestones, and 100,000 stock options vesting 33.3% on June 1, 2026, 33.3% on December 1, 2026, and 33.3% on December 1, 2027.
NRx Pharmaceuticals, Inc. appointed Joseph M. Casper, age 75, as its Chief Operating Officer, effective January 27, 2026. He brings 35 years of healthcare experience, including senior roles advising major payer, provider, and academic medical center organizations and involvement in an early medical record aggregation platform used by more than 15 million patients.
Mr. Casper’s compensation includes an expected annual base salary of $250,000, a target bonus of 25% of base salary tied to agreed milestones, and 100,000 stock options vesting 33.3% on June 1, 2026, 33.3% on December 1, 2026, and 33.3% on December 1, 2027.